New fermentation and purification production technologies for menaquinone-7 for promoting bone and cardiovascular health

促进骨骼和心血管健康的 Menaquinone-7 新型发酵和纯化生产技术

• 批准号: LP100100347
• 负责人: Prof Fariba Dehghani
• 金额: $ 15.99万
• 依托单位: The University of Sydney
• 依托单位国家: 澳大利亚
• 项目类别: Linkage Projects
• 财政年份: 2010
• 资助国家: 澳大利亚
• 起止时间: 2010-05-20 至 2013-12-31
• 项目状态: 已结题
• 来源: https://dataportal.arc.gov.au/RGS/Web/Grants/LP100100347
• 关键词: New; fermentation; purification; production; technologies

We will develop a significantly more cost-efficient and environmentally friendly process for the production of vitamin K (menaquinone-7, or MK7) to manufacture food supplements for humans and animals. MK7 will increase bone regeneration and minimise the risk of cardiovascular disease. It has the potential to reduce the costs of these conditions for the community, and to increase the quality of life for Australia's ageing population. Orthopaedic diseases are also a major veterinary issue, and our advance should make MK7 a more widely used available supplementary food for animals such as horses and dogs.

我们将开发一种更具成本效益和环境友好的生产维生素K（甲基萘醌-7或MK 7）的工艺，以生产人类和动物的食品补充剂。MK 7将增加骨再生，并将心血管疾病的风险降至最低。它有可能减少社区为这些条件付出的代价，并提高澳大利亚老龄人口的生活质量。骨科疾病也是一个主要的兽医问题，我们的进步应该使MK 7成为一种更广泛使用的动物补充食品，如马和狗。